← Back to Search

Neuromodulation

Neuromodulation for Gastroparesis (TNM-DGp Trial)

N/A
Recruiting
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No known mucosal disease
Men or women age less than 85
Must not have
Prior gastric surgery (fundoplication, gastric resection or pyloroplasty)
Enteral or parenteral feeding
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks

Summary

This trial is testing a new noninvasive treatment for gastroparesis that uses neuromodulation to improve symptoms. The hypothesis is that this new treatment will be better than a sham treatment at improving symptoms.

Who is the study for?
This trial is for English-speaking adults under 85 with diabetic gastroparesis, experiencing moderate to severe symptoms despite treatment. Participants must have been on stable medication doses for 30 days, excluding certain drugs like opioids. It's not open to those with prior gastric surgery, metal implants unsafe for MRI, feeding tubes, recent changes in neuromodulator dosage, pregnant or nursing women, and several other conditions.
What is being tested?
The study tests a new noninvasive therapy called Thoracic Spinal Nerve Magnetic Neuromodulation (ThorS-MagNT) at different frequencies (1Hz and 10Hz) against sham stimulations. The goal is to see if this can improve symptoms of diabetic gastroparesis by affecting nerve pathways between the spine and gut or brain structures involved in autonomic functions.
What are the potential side effects?
Since this is a noninvasive neuromodulation therapy using magnetic stimulation rather than drugs or surgery, side effects are expected to be minimal. However, specific side effect details will likely be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have any known diseases affecting the moist tissues of my body.
Select...
I am younger than 85 years old.
Select...
I am younger than 85 years old.
Select...
I do not have any known diseases affecting the moist linings of my body.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had surgery on my stomach before.
Select...
I am receiving nutrition through a feeding tube or IV.
Select...
I have slow stomach emptying after surgery.
Select...
I am currently taking medication that stimulates my nervous system.
Select...
I do not have severe heart disease or irregular heartbeats.
Select...
I have a history of seizures.
Select...
I have an active inflammatory bowel condition.
Select...
I have a diagnosed digestive disorder and less than one bowel movement every 2 weeks.
Select...
I have a blockage in my digestive tract.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Responder rate
Secondary study objectives
Quality of life (QOL)

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: 1Hz ArmActive Control1 Intervention
ThorS-MagNT treatment intervention with 2400 total stimulations at 1Hz with the magnetic coil.
Group II: 10Hz ArmActive Control1 Intervention
ThorS-MagNT treatment intervention with 2400 total stimulations at 10Hz with the magnetic coil.
Group III: Sham ArmPlacebo Group1 Intervention
Sham intervention with 2400 total sham stimulations with the magnetic coil.

Find a Location

Who is running the clinical trial?

Augusta UniversityLead Sponsor
215 Previous Clinical Trials
85,642 Total Patients Enrolled
1 Trials studying Gastroparesis
12 Patients Enrolled for Gastroparesis

Media Library

ThorS-MagNT (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05273788 — N/A
Gastroparesis Research Study Groups: 1Hz Arm, 10Hz Arm, Sham Arm
Gastroparesis Clinical Trial 2023: ThorS-MagNT Highlights & Side Effects. Trial Name: NCT05273788 — N/A
ThorS-MagNT (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05273788 — N/A
~3 spots leftby Jan 2025